http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-815885-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c24684033fba97d1ad845ce453a57e3
filingDate 1957-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1959-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GB-815885-A
titleOfInvention Sulphonyl-ureas and a process for their manufacture
abstract The invention comprises sulphonyl urea compounds of the formula R-SO2-NH-CO-NHR wherein R is a phenyl radical optionally containing one or two substituents selected from alkyl or alkoxy groups, preferably containing up to 8 carbon atoms, and halogen atoms, or is an aliphatic or cycloaliphatic hydrocarbon radical of 3 to 8 carbon atoms, or a naphthalene-(2), a 5 : 6 : 7 : 8 - tetrahydro - naphthalene - (2) or a 4-phenoxyphenyl radical and R1 is the radical C6H5-(CH2)n-, wherein n is a whole numbe from 2 to 4 and salts of these compounds with bases which give physiologically tolerable salts. The compounds are prepared by known methods for the production of sulphonyl ureas, for example: (1) a sulphonyl isocyanate of the formula R-SO2-NCO is reacted with an amine R1NH2 or conversely an isocyanate R1NCO is reacted with a sulphonamide R-SO2NH2; (2) a sulphonyl urethane of the formula R.SO2.NH.COO.R2 is reacted with an amine R1NH2, or, conversely, a sulphonamide R.SO2NH2 is reacted with a urethane of the formula R1.NH.COO.R2, R2 being a hydrocarbon radical; (3) a sulphonyl-carbamoyl halide of the formula R.SO2NH.CO.Hal is reacted with an amine R1NH2, or a sulphonamide R.SO2.NH2 is reacted with a carbamoyl halide R1NH.CO.Hal; (4) a urea containing an aliphatic or cycloaliphatic substituent is reacted with a sulphonamide, or, conversely, a sulphonyl urea R.SO2.NH.CO.NH2 is reacted with an amine R1NH2; (5) a sulphonyl halide R-SO2-Hal is reacted with an iso-urea ether and the resulting sulphonyl iso-urea ether is converted to the desired sulphonyl urea; (6) the corresponding sulphonyl thio-urea is decomposed by means of heavy metal oxides or by oxidation, for example by sodium peroxide or nitrous oxide to give the urea derivative; and (7) the corresponding sulphonyl guanidine obtainable by reaction of a sulphonyl-cyanamide with an amine is hydrolysed. Many variations on these methods, wherein the starting materials may be replaced by salts and addition products or by compounds which decompose to form the required starting materials are suggested. The products are used therapeutically for the oral treatment of diabetes. Examples describe the preparation of N-cyclohexane-sulphonyl-, N-(4 - methoxy - 3 - methyl - benzenesulphonyl) -, N - 4 - methylbenzenesulphonyl -, N - 3 : 4 - dimethylbenzenesulphonyl -, N - naphthalene - (2) - sulphonyl -, N - isopropylbenzenesulphonyl -, N - (3 - chloro - 4 - methyl - benzenesulphonyl) -, N - pentane - 3 - sulphonyl - and N - 4 - phenoxyphenylsulphonyl -, N1 - (b - phenylethyl)-urea and N-cyclohexanesulphonyl-N1 - phenylpropyl - urea; N - 4 - methylbenzenesulphonyl - N1 - phenylpropyl - urea and N - 4 - methylbenzenesulphonyl - N1 - 4 - phenylbutyl-urea. Sulphonyl-urethanes.-The ethyl esters of cyclohexane - sulphonyl -, 3 - methyl - 4 - methoxy - benzenesulphonyl -, p - toluenesulphony -, 3 - chloro - 4 - methyl - benzenesulphonyl - and pentane-3-sulphonyl-, carbamic acid and the methyl esters of p-toluenesulphonyl-, 3 : 4-dimethyl - benzenesulphonyl - naphthalene - 2 - sulphonyl -, 4 - isopropylbenzenesulphonyl - and 4 - phenoxybenzenesulphonyl -, carbamic acid are made by treating the appropriate sulphonamide with ethyl or methyl chloroformate. Cyclohexane - sulphonyl - isocyanate is made from cyclohexane-sulphonamide and phosgene. Specifications 595,472, [Group IV], and 604,259 are referred to.ALSO:Preparations for the treatment of diabetes comprise compounds of the formula R-SO2-NH-CO-NHR1 wherein R is a phenyl radical optionally containing one or two substituents selected from alkyl or alkoxy groups, preferably containing 1-8 carbon atoms and halogen atoms, or is an aliphatic or cycloaliphatic hydrocarbon radical of 3-8 carbon atoms, or a naphthalene-(2), a 5 : 6 : 7 : 8 - tetrahydronaphthalene - (2) or a 4-phenoxyphenyl radical and R1 is the radical C6H5-(CH2)nwherein n is a whole number from 2 to 4, and salts of these compounds with bases which give rise to physiologically tolerable salts, e.g. ammonium, alkali metal and alkaline earth metal and organic base salts, in conjunction with a pharmaceutical carrier. The preparations are preferably administered orally. Many suitable active sulphonamides of the above general formula are specified (see Group IV (b)). Specifications 595,472, [Group IV], and 604,259, [Group IV (b)], are referred to.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3347914-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3621057-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3547618-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5981595-A
priorityDate 1956-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18783552
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559564
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5641
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13487255
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID75536
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414671928
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410519900
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID223
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID430824729
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86660807
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6371
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID430821762
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID105034
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID948
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410506103
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID429253641
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414671822
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86676953
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID277
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID931
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154187023
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474406
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5333
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502284
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419539344
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425199706
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21950190
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414671805
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11819083
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419480927
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID77898
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID429253642
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415764006
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483880
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414671823
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID153776989
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448808613
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20220212
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21584239
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558836
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22182847
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451733884
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID153776990
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID432142809
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422981231
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1176
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423007479

Total number of triples: 60.